Phenomic AI aims to enhance patient outcomes by creating new cancer medications targeting the tumor stroma, a significant barrier blocking current treatments. Utilizing one of the world's largest single-cell RNA datasets, their platform leverages advanced machine learning to analyze single-cell data at scale, specifically focusing on the tumor stroma. This innovative approach addresses treatment resistance in solid tumors such as breast, colorectal, and pancreatic cancers. Their scTx platform allows for detailed exploration of cell types and target expression, combining expertise in deep learning with biological insights. The team includes seasoned professionals with extensive experience in biopharma and stromal biology, supported by eminent advisors in immune-oncology and cell biology. Phenomic AI aims to transform cancer care through targeted therapies while navigating strategic partnerships for research continuity and therapeutic advancements.
• single-cell rna data analysis
• deep-learning tools for target identification
• preclinical and clinical development strategy
• collaboration with esteemed advisors
• advanced machine learning in drug discovery
Average Rating: 0.0
5 Stars:
0 Ratings
4 Stars:
0 Ratings
3 Stars:
0 Ratings
2 Stars:
0 Ratings
1 Star:
0 Ratings
No ratings available.
AI platform for drug discovery using advanced data analytics and machine learning.
View DetailsAI-powered platform for drug discovery using novel therapeutics and machine learning.
View DetailsAI-powered small molecule drug discovery platform accelerating drug development.
View DetailsA federated AI framework that integrates decentralized data sources for AI development.
View Details